MENA Tissue Diagnostic Market: Current Analysis and Forecast (2024-2032)

Tissue diagnostics refers to the medical process of examining tissue samples from a patient to diagnose diseases or conditions. This crucial procedure helps healthcare professionals identify abnormalities, determine the nature of a disease, and plan appropriate treatment strategies. Pathologists and other trained specialists examine the tissue sample under a microscope. They look for any signs of disease, such as cancerous cells or infections, and analyze the tissue's structure and composition to diagnose accurately.

The MENA Tissue Diagnostic Market is expected to grow at a robust CAGR of 6.5% during the forecast period (2024-2032). This is mainly because of the rise in disease incidence and the growing need for diagnostics, which include key factors that are creating a push towards the tissue diagnostic market in the MENA region. Chronic diseases, including cancer, cardiovascular diseases, and diabetes, are on the increase in the Gulf Cooperation Council countries, including Qatar, Bahrain, Oman, Jordan, and Lebanon, because of old-age population, changes in lifestyle and influences factors, and environmental impacts. As per the United Nations Population Fund (UNFPA), in 2024, the United Arab Emirates is going through a demographic transition as the number of persons aged 60+ is expected to increase more than six-fold between 2020 - 2050 from about 311,000 (3.1% of the total population) to 2 million (19.7%).

Based on the product, the market is segmented into instruments, consumables, and reagents. Among them, the consumables and reagents category held the largest share of the market in 2023. With the increasing adoption of molecular diagnostics in tissue diagnostics, there is a growing demand for specialized reagents tailored to molecular testing applications. Moreover, market players in this segment focus on developing innovative products that improve the efficiency and accuracy of tissue diagnostic procedures while ensuring cost-effectiveness. Therefore, the demand for consumables and reagents in tissue diagnostics drives growth in the overall tissue diagnostics market.

Based on the technology, the market is segmented into immunohistochemistry, in-situ hybridization, digital pathology and workflow management, and others. Among them, digital pathology and workflow management are expected to grow in the healthcare market with a significant CAGR during the forecast period (2024-2032). They enhance collaboration among healthcare professionals and facilitate second opinions and consultations by digitizing glass slides and enabling remote access to pathology images. The integration of artificial intelligence (AI) algorithms further enhances the interpretation and analysis of pathological images, leading to more accurate and reproducible diagnoses.

Based on application, the market is segmented into prostate cancer, breast cancer, lung cancer, gastric cancer, and other cancers. Among them, breast cancer held the largest share of the market in 2022. This is due to the surge in the burden of breast cancer and the emphasis on early detection and personalized treatment. As breast cancer awareness grows, screening programs expand, and therapeutic strategies become increasingly targeted, the demand for advanced tissue diagnostic technologies and services in breast cancer diagnosis and management continues to drive the growth of the tissue diagnostic market.

Based on end-user, the market is segmented into diagnostic laboratories, hospitals, contract research organizations (CROS), and others. Among them, Hospitals held a dominant share of the market in 2023. This is due to hospitals in the MENA region adopting integrated diagnostic approaches that combine tissue diagnostics with other modalities such as imaging, genetic testing, and clinical pathology. These technologies enable hospitals to conduct comprehensive tissue analysis, identify disease biomarkers, and provide personalized treatment plans tailored to individual patient profiles.

For a better understanding of the market adoption of the tissue diagnostic industry, the MENA market is analyzed based on its worldwide presence in countries such as UAE, Saudi Arabia, Egypt, Kuwait, and the Rest of the MENA. Kuwait is expected to grow with the highest CAGR of the market during the forecast period (2024-2032). Kuwait boasts one of the highest healthcare expenditures per capita globally, reflecting its commitment to providing high-quality medical services to its citizens. Tissue diagnostics are crucial in Kuwait's healthcare system by enabling early disease detection, accurate diagnosis, and personalized treatment planning. The country's well-developed healthcare infrastructure and focus on medical innovation and technology adoption create a conducive environment for expanding tissue diagnostic services. For instance, in 2021, Medovate, a medical device manufacturer in the U.K., announced a partnership in the Middle East. The Cambridge-based specialist has teamed up with Kuwait's Omneya Medical Co. to distribute its SAFIRA (SAFer Injection for Regional Anesthesia) device in the Gulf country. As Kuwait continues prioritizing healthcare excellence and patient-centered care, tissue diagnostics are poised to play an increasingly integral role in shaping the country's healthcare landscape.

Some of the major players operating in the market include Roche Diagnostics Middle East, Abbott, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Siemens Healthineers AG, Koninklijke Philips N.V., The Menarini Group, Sakura Finetek USA, Inc., AFMS (Abdulla Fouad for Medical Supplies & Services).